Israeli study confirms Pfizer/BioNTech COVID-19 vaccine efficacy

On Sunday the largest of Israel’s four health care providers released a study that compared infections in 600,000 Israelis who had received the vaccine compared to 600,000 who were not immunized.
The study found a 94 percent drop in symptomatic infections and a 92 percent drop in serious cases of the disease among those vaccinated. It said “the efficacy of the vaccine is preserved in every age group,” particularly a week after the second dose of the vaccine.

The researchers said the preliminary findings of the ongoing research “is aimed at emphasizing to the population that has yet to vaccinate that the vaccine is highly effective and prevents serious illness.”